Skip to main content
. 2009 Dec 24;2010:497429. doi: 10.1155/2010/497429

Table 6.

Recommendation for secondary cytoreduction based on disease free interval and number of recurrence site.

Disease free Single site Multiple site Carcinomatosis
interval no carcinomatosis
6–12 Mo offer SC consider SC No SC
12–30 Mo offer SC offer SC consider SC
>30 Mo offer SC offer SC offer SC

DFI: disease free interval. SC: secondary cytoreduction. Chi et al. [21].